Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
82.19
+1.39 (1.72%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Cytokinetics Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for Cytokinetics stock have an average target of 102, with a low estimate of 69 and a high estimate of 140. The average target predicts an increase of 24.10% from the current stock price of 82.19.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock from 22 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 11 | 12 | 12 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 20 | 20 | 21 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho Securities | Mizuho Securities | Buy Maintains $100 → $118 | Buy | Maintains | $100 → $118 | +43.57% | Jun 23, 2026 |
| Citi | Citi | Buy Reiterates $99 | Buy | Reiterates | $99 | +20.45% | Jun 17, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $103 | Buy | Maintains | $103 | +25.32% | Jun 17, 2026 |
| Bank of America Securities | Bank of America Securities | Hold Maintains $67 → $83 | Hold | Maintains | $67 → $83 | +0.99% | Jun 17, 2026 |
| Needham | Needham | Buy Maintains $102 | Buy | Maintains | $102 | +24.10% | Jun 16, 2026 |
Financial Forecast
Revenue This Year
109.27M
from 88.04M
Increased by 24.12%
Revenue Next Year
387.38M
from 109.27M
Increased by 254.51%
EPS This Year
-6.43
from -6.54
EPS Next Year
-4.75
from -6.43
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 182.4M | 544.5M | |
| Avg | 109.3M | 387.4M | |
| Low | 76.7M | 315.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 107.1% | 398.3% | |
| Avg | 24.1% | 254.5% | |
| Low | -12.9% | 188.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -4.80 | -3.39 | |
| Avg | -6.43 | -4.75 | |
| Low | -7.47 | -5.61 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.